Scott A. Scharfenstein Jr.

Scott Scharfenstein practices at St. Tammany Parish Hospital in Covington, Louisiana, part of St. Tammany Health System.

Scott Scharfenstein's NPI, 1538666193, was assigned on April 10, 2018. Scott Scharfenstein holds Mississippi license 30069.

Scott Scharfenstein's primary practice is St. Tammany Parish Hospital, at 1202 S Tyler Street, Covington, LA 70433 in St. Tammany Parish. The practice phone is (985) 898-4000.

Scott Scharfenstein's primary practice is St. Tammany Parish Hospital in Covington, Louisiana, part of St. Tammany Health System. Scott Scharfenstein is also affiliated with Ochsner Medical Center - New Orleans. The medical group on file is LCMC Anesthesia. Dmand AI also links Scott Scharfenstein to 2 more hospitals, 5 medical groups and 1 clinical lab, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Scott Scharfenstein practices, 5 sites in all. Vendor and product names are available with a free account.

Anesthesiology is Scott Scharfenstein's primary specialty in the NPI Registry, under taxonomy code 207L00000X. Scott Scharfenstein is licensed in Mississippi.

CMS data shows 747 Medicare services from Scott Scharfenstein across 23 procedure codes in 2024, for 764 Medicare patients. Medicare paid $41,084 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 764 Medicare patients who saw Scott Scharfenstein in 2024. The largest group is 65 to 74, with 340 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Scott Scharfenstein's median patient age at 68, with 56% women.

Scott Scharfenstein accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 7 general payments to Scott Scharfenstein from 2 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $118.